Press Releases
Stay updated on the latest Vistagen News and get the details about important events, public financial reports, and our product pipeline updates.
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/06/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the U.S.
Nov 09, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/09/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN) , a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported its financial results for its
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/06/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the European Patent
Oct 26, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/26/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the U.S.
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/28/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced receiving a Notice of
Sep 06, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/06/17 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (VistaGen or the Company), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced
Aug 31, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/31/17 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN) ("VistaGen" or the "Company"), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system disorders, today announced
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/21/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the appointment of David
Aug 14, 2017
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/14/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN) , a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported its financial results for its
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/08/17 -- VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the Company has
